Portal de Periódicos da CAPES

A Randomized Trial of Adjuvant Combination Chemotherapy With Or Without Prednisone in Premenopausal Breast Cancer Patients With Metastases in One to Three Axillary Lymph Nodes

1985; American Association for Cancer Research; Volume: 45; Issue: 9 Linguagem: Inglês

1538-7445

Aron Goldhirsch, J. Stjemsward, Wolfgang Hartmann, B. Davis, David T. Zava, V. Craig Jordan, A. Zimmermann, Archie H. Baggenstoss, Christina Wiedmer, Claudia Ramminger, Richard D. Gelber, K. Price, K. Stanley, Marvin Zelen, M. Istey, Maddy Parsons, L. Szymoniak, P Helman, A Hacking, A. Gudgeon, Andrew J. Tiltman, Eugene B. Dowdle, C. G. Schmidt, R. Zchaber, F. Sch�ning, K. Hköffken, L.-D. Leder, Holger Ludwig, R. Cailles, Carl‐Magnus Rudenstam, J Säve-Söderbergh, E. Cahlin, C Johnsén, Jan Mattsson, H Salander, Jan Olof Svensson, Stefan Nilsson, J. Pomander, L-Å Mattsson, C. G. Bäckstrom, S. Bergegårdh, Sara Dahlin, N. Fahl, Y Hessman, Stig B. Holmberg, O. Ruusvik, L. Niklasson, U Ljungqvist, Charlotte Andersson, L. Ivarsson, Joachim Mark, G Ostberg, I. M. Dahl,

Breast Implant and Reconstruction

The impact of adding low-dose continuous prednisone (7.5 mg daily) to an adjuvant cyclophosphamide-methotrexate-5-fluorouracil chemotherapy regimen was investigated in a randomized trial of 505 pre- and perimenopausal patients with operable breast cancer and one to three axillary lymph node mA©tastases (Ludwig Breast Cancer Study I). As a consequence of lower hematological toxicity a significantly higher dose of cyclophosphamide-methotrexate-5-fluorouracil could be administered with added prednisone (P < 0.0001). However, at a median followup of 48 months, no improvement in terms of disease-free survival (P = 0.35) or overall survival (P = 0.73) was observed. Induced amenorrhea was associated with a longer disease-free survival for younger patients, patients who received lower cyclo1Members of the Ludwig Breast Cancer Study Group are listed by institution.